[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dilated-cardiomyopathy-dcm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dilated-cardiomyopathy-dcm":440},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,44,77,111,134,164,190,213,242,259,282,302,320,345,371],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632638",false,"NCT07516288","Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy","Safety and Efficacy of Second Infusion of Autologous Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy","Inclusion Criteria:\n\n* ≥18 years and ≤75 years of age, with a confirmed diagnosis of dilated cardiomyopathy.\n* Patients who previously received a single infusion of immunosuppressive CAR-DC (iCDC) therapy and, at 6 months after the first treatment, failed to maintain improvement in cardiac function, with cardiac function declining to baseline levels prior to treatment. These patients should have persistent heart failure symptoms that cannot be adequately improved, with left ventricular ejection fraction (LVEF) \\\u003C35%, New York Heart Association (NYHA) functional class III-IV, and INTERMACS profile 3-6.\n* Able to verbally confirm understanding of the risks, benefits, and alternative treatment options of the second administration of iCDC therapy, and willing to participate in the study. The participant or his\u002Fher legal representative must provide written informed consent prior to enrollment.\n* Hematocrit \\>30%, lymphocyte count \\>0.5 × 10⁹\u002FL, and platelet count \\>60 × 10⁹\u002FL.\n\nExclusion Criteria:\n\n* Severe renal failure or requirement for renal dialysis, or serum creatinine \\>2.5 mg\u002FdL.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 5.0 times the upper limit of normal (ULN), or total bilirubin \\>3 mg\u002FdL.\n* Presence of active infections at screening, including: Active hepatitis B infection with hepatitis B virus DNA \\>1000 copies\u002FmL by PCR testing; Hepatitis C virus infection; Syphilis; Human immunodeficiency virus (HIV) infection; Uncontrolled systemic fungal, bacterial, viral, or other pathogenic infections.\n* Severe hemodynamic instability (e.g., shock).\n* Known contraindications to the investigational product or study-related procedures.","ALL","18 Years","75 Years",{"count":19,"type":20},5,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy.\n\nPrevious clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion is safe and whether it can further improve cardiac function in this patient population.",[26,27],"Dilated Cardiomyopathy (DCM)","Heart Failure",[29,30],"end-stage dilated cardiomyopathy","FAP immunosuppressive CAR-DC","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-05-11",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100625729","NCT07426419","An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)","A Phase 1\u002F2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Trial to Assess the Safety, Tolerability, Pharmacodynamics, and Preliminary Efficacy of AFTX-201 Administered to Adult Participants With BCL2-Associated Athanogene 3 (BAG3) Mutation-Associated Dilated Cardiomyopathy: UPBEAT Trial","UPBEAT","Inclusion Criteria:\n\nMale or female, 18 to 55 years of age\n\nTruncating mutation in BAG3\n\nDilated cardiomyopathy with left ventricular ejection fraction (LVEF) \\\u003C 45%\n\nNYHA Class II or III heart failure symptoms\n\nNT-proBNP ≥ 300 pg\u002FmL for subjects in sinus rhythm or paced rhythm, or ≥ 600 pg\u002FmL for subjects in atrial fibrillation\n\nWilling and able to sign informed consent and comply with study procedures\n\nExclusion Criteria:\n\nPrior myocardial infarction, heart transplant, or presence\u002Frequirement of a left ventricular assist device (LVAD)\n\nIV therapy with positive inotropes, vasodilators, or diuretics for heart failure within 30 days prior to enrollment\n\nPositive neutralizing antibodies to ATC-0187\n\nAny condition that, in the investigator's opinion, would place the subject at undue risk or interfere with study participation or interpretation of results","55 Years",{"count":53,"type":20},22,[23,55],"PHASE2","This is a Phase 1\u002F2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation",[26,58],"BAG3 Mutation Associated Dilated Cardiomyopathy",[60,61,62,63,64,65,66],"AFTX-201","Gene Therapy","AAV","BAG3","Dilated Cardiomyopathy","DCM","ATC-0187","2026-06-30",{"date":34,"type":35},{"date":70,"type":20},"2026-06",{"date":72,"type":20},"2032-12",{"name":74,"class":75},"Affinia Therapeutics","INDUSTRY",2,{"id":78,"slug":4,"hasResults":10,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100603501","NCT07137338","A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy","A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (BAG3-DCM)","Inclusion Criteria:\n\nSubjects are eligible for inclusion into the study only if all the following criteria apply:\n\n1. Male or female between 18 and 65 years of age at the time of signing the informed consent\n2. Capable of and willing to provide signed informed consent\n3. Clinical diagnosis of DCM defined as and requiring each of the following:\n\n   1. Mild to moderate systolic dysfunction (LVEF ≥ 25% and ≤ 45%) by echocardiography or CMR performed within 3 months of enrollment.\n   2. Absence of severe coronary artery disease (\\>70% stenosis) or active myocardial ischemia as the etiology of LV systolic dysfunction\n   3. Absence of uncontrolled hypertension, significant cardiac valve disease (i.e., greater than moderate in severity), infiltrative disorder, or systemic disease known to cause cardiomyopathy.\n4. Documentation of a pathogenic or likely pathogenic variant in BAG3\n5. History of ICD implantation ≥ 3 months prior to enrollment\n6. NYHA Class II or III HF symptoms with stable HF therapeutic guideline-directed medical regimen for 30 days prior to enrollment\n\nExclusion Criteria:\n\n1. CV disease that may be related to a genetic etiology other than a BAG3 pathogenic or likely pathogenic variant.\n2. Previous participation in a study of gene transfer or gene editing.\n3. I.V. inotropic, vasodilator, or diuretic therapy ≤ 30 days prior to enrollment.\n4. History of intracardiac thrombosis or arterial thromboembolic events\n5. Severe RV dysfunction assessed by echocardiogram or CMR ≤ 12 months prior to screening\n6. LVEF \\\u003C 25% by echocardiogram or CMR at ≤ 3 months prior to screening\n7. NYHA Class I or IV HF","65 Years",{"count":85,"type":20},8,[23],"This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.",[26],[90,91,92,93,94,65,63,95,96,61,27,97,98,99,100,101,102],"Cardiomyopathy","Dilated","BAG3 Protein","human","dilated cardiomyopathy","BCL2-associated Athanogene 3","Genetic Cardiomyopathy","Ventricular Arrhythmia","Cardiovascular Diseases","Cardiomyopathies","Heart Diseases","Inherited heart disease","AAVrh.74","2026-06-26",{"date":67,"type":35},{"date":70,"type":20},{"date":107,"type":20},"2029-06",{"name":109,"class":75},"Rocket Pharmaceuticals Inc.",3,{"id":112,"slug":4,"hasResults":10,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100630367","NCT07486752","BAG3-DCM Natural History Study","An Observational Study of Patients With Dilated Cardiomyopathy (DCM) Associated With Pathogenic BAG3 Variants","Key Inclusion Criteria:\n\nSubjects are eligible for inclusion into the study only if all the following criteria apply:\n\nGeneral:\n\n1. Adult patients 18 years or older at the time of providing informed consent (i.e., signing the ICF).\n2. Capable and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.\n3. Diagnosis of DCM as defined by mild to moderate systolic dysfunction performed within 12 months of enrollment and confirmed by the principal investigator that the DCM is predominantly non-ischemic.\n4. Documentation of a pathogenic or likely pathogenic variant in BAG3 by a CLIA-certified or equivalent genetic testing laboratory.\n5. NYHA class I-III\n\nKey Exclusion Criteria:\n\nAll Cohorts:\n\n1\\. Concurrent enrollment in any other clinical investigation involving use of an investigational agent for any condition at time of enrollment to this study that could confound interpretation of this study results 2. Previous treatment with gene therapy 2. Gene testing indicates that the patient's arrhythmia or cardiomyopathy may be related to a genetic etiology other than BAG3 variant.\n\n4\\. NYHA class IV HF. 5. Presence or requirement for MCS or predicted need for MCS or heart transplantation within 6 months prior to enrollment.\n\n6\\. Prior heart transplantation. 7. Known infection with human immunodeficiency virus (HIV). 8. Unwillingness to comply with study procedures, including follow-up as specified by this protocol, or unwillingness to fully cooperate with the investigator.",{"count":118,"type":20},30,"OBSERVATIONAL","The goal of this international observational study is to learn about the natural history of Dilated Cardiomyopathy (DCM) arising from pathogenic BAG3 variants in adult patients ≥18 years of age.",[26,98,100,122],"Genetic Diseases",[63,64,124,90,95],"BAG3-DCM","NOT_YET_RECRUITING","2026-03-17",{"date":128,"type":35},"2026-03-20",{"date":130,"type":20},"2026-05",{"date":132,"type":20},"2033-03",{"name":109,"class":75},{"id":135,"slug":4,"hasResults":10,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":119,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":43},"100625305","NCT07420907","Study of the Progression of Chronic Cardiovascular Conditions","A Non-interventional Observational Study of the Sustained Use of Prolaio Digital Health Devices to Monitor the Natural History of Chronic Cardiovascular Conditions in Ambulatory Patients","OCORO","Inclusion Criteria:\n\n* 18 years of age and older\n* Ability to understand study assessments and give informed consent to data collection\n* Ability to comply with the study protocol\n* Ability to understand and respond to instructions in English\n* Has diagnosis of qualifying Cardiovascular Disease(s) (CVD) including but not limited to: HF, AS, HCM, HTN, DCM, etc.\n* Resides in the United States\n\nExclusion Criteria:\n\n* Allergy to adhesive used in biosensor patch\n* Life threatening disease process outside of area under study, such as actively treated cancer or pre\u002Fpost-transplant such as hepatic failure; end-stage renal disease.\n* Severe CVD defined by hospital admission for cardiac diagnosis within 30 days of enrollment or documentation of NYHA functional class IV\n* Self-reported weight of 400 pounds or greater",{"count":142,"type":20},5000,"5 Years","This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.",[146,27,147,148,149,150,151,152,153,26,64,154],"Cardiovascular Disease (CVD)","Aortic Stenosis","Aortic Stenosis Disease","Hypertension","Hypertension (HTN)","Hypertrophic Cardiomyopathy Patients","Hypertrophic Cardiomyopathy Without Obstruction","Hypertrophic Cardiomyopathy, Obstructive","Dilated Cardiomyopathy, Familial","2026-02-16",{"date":157,"type":35},"2026-02-19",{"date":159,"type":35},"2025-10-30",{"date":161,"type":20},"2030-10",{"name":163,"class":75},"Prolaio",{"id":165,"slug":4,"hasResults":10,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":171,"conditions":172,"keywords":178,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":43},"100620597","NCT07359690","Multimodal Analysis of Endomyocardial Biopsies","Inclusion Criteria:\n\n* Patients aged \\>18 years with a clinical indication for endomyocardial biopsy.\n* Patients capable of providing informed consent who have signed the consent form for participation in the study.\n\nExclusion Criteria:\n\n* Patients without a clinical indication for endomyocardial biopsy (EMB).\n* Pregnant individuals.\n* Patients incapable of providing informed consent.\n* Women of childbearing potential who are not using adequate contraception.",{"count":170,"type":20},216,"The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.\n\nThe main aim is:\n\n-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.\n\nParticipants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.",[173,26,174,175,176,99,177],"Heart Transplantation","Hypertrophic Cardiomyopathy (HCM)","Myocarditis, Pericarditis","Amyloidosis Cardiac","Sarcoidosis of the Heart",[179,180],"Endomyocardial biopsy","Multimodal analysis","2026-01-15",{"date":183,"type":35},"2026-01-22",{"date":185,"type":35},"2025-10-27",{"date":187,"type":20},"2028-09-30",{"name":189,"class":42},"University Hospital, Essen",{"id":191,"slug":4,"hasResults":10,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":196,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":43},"100620209","NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",true,{"count":198,"type":20},2000,"The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[201,174,26,202,203],"Myocardial Infarction (MI)","Arrhythmogenic Cardiomyopathy","Myocarditis","2026-01-12",{"date":206,"type":35},"2026-01-21",{"date":208,"type":35},"2020-03-01",{"date":210,"type":20},"2026-12-01",{"name":212,"class":42},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":214,"slug":4,"hasResults":10,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":10,"sex":15,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100619636","NCT07347197","Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)","A Phase I\u002FII Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction","EMERALD","Inclusion Criteria:\n\n* Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on institutional assessment on screening echocardiographic assessment\n* New York Heart Association (NYHA) cardiac function classification of grade II or III at screening\n* Other Criteria apply, please contact the investigator\n\nExclusion Criteria:\n\n* Patients with cardiac devices such as pacemakers, implantable cardioverter defibrillators (ICDs), or cardiac resuscitation-enabled implantable cardioverter defibrillators (CRT-Ds)\n* Patients with heart failure due to the primary disease hypertrophic cardiomyopathy (including the dilated phase), restrictive cardiomyopathy, amyloidosis, takotsubo cardiomyopathy, congenital heart disease, cardiac sarcoidosis, or constrictive pericarditis\n* Other Criteria apply, please contact the investigator","20 Years","80 Years",{"count":223,"type":20},14,[23,55],"The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.",[27,227,228,26],"Ischemic Heart Failure","Ischemic Heart Disease",[27,230,228,26,231,232],"Ischemic heart failure","iPSC","cell therapy","2026-01-08",{"date":235,"type":35},"2026-01-16",{"date":237,"type":20},"2026-01-01",{"date":239,"type":20},"2030-01-31",{"name":241,"class":75},"Heartseed Inc.",{"id":243,"slug":4,"hasResults":10,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":43},"100615494","NCT07293338","Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy","Inclusion Criteria:\n\n* Dilated cardiomyopathy comfirmed by echocardiography: LVDd \\> 55 mm in men or \\> 50 mm in women.\n* Clinically evident congestive heart failure: Compatible symptoms and signs, and BNP ≥ 35 pg\u002FmL or NT-proBNP ≥ 125 pg\u002FmL, and LV systolic dysfunction defined by LVEF \\\u003C 45 %.\n* Coronary angiography showing stenosis ≤ 50 % in all major epicardial vessels.\n\nExclusion Criteria:\n\n* Patients with coronary artery disease, hypertensive heart disease, rheumatic valvular heart disease, myocarditis, and other secondary cardiomyopathies.\n* poor angiographic image quality",{"count":248,"type":20},330,"The goal of this observational study is to learn about the long-term prognostic of coronary microvascular dysfuction in Patients with Dilated Cardiomyopathy.\n\nThe main question it aims to answer is: Does the coronary microvascular dysfunction impact the outcomes in Patients with Dilated Cardiomyopathy.",[26],"2025-12-18",{"date":253,"type":35},"2025-12-19",{"date":255,"type":20},"2026-01-06",{"date":257,"type":20},"2027-12-01",{"name":41,"class":42},{"id":260,"slug":4,"hasResults":10,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":196,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":43},"100604101","NCT07145138","UIC Multi-Ethnic DCM Registry","University of Illinois Chicago (UIC) Multi-Ethnic Dilated Cardiomyopathy (DCM) Registry","Inclusion Criteria:\n\n* Must be at least 18 years of age and be admitted to or seen at a UIH site.\n* Subjects must be willing and able to give written, informed consent\n\nExclusion Criteria:\n\n* Adults who are unable to provide consent\n* Women who are pregnant at the baseline visit,\n* Prisoners\n* Individuals who are not yet adults (infants, children, teenagers).",{"count":266,"type":20},1500,"Dilated cardiomyopathy (DCM), a condition where the heart loses its ability to pump blood throughout the body, is a common cause of death in the United States (US). It affects minorities more frequently and appears to causes greater harm than Whites. However, almost all research related to DCM has been performed in Whites, where up to half of cases run in the family. Several genes have been identified that cause the disease, but we are unsure if these same genes are also responsible for DCM in African Americans or Hispanic\u002FLatino patients. The impact of various medical, social, and financial stressors on the severity of the disease in ethnic minorities also remains unclear. The investigators believe that certain genes are more common in different racial and ethnic groups and the greater medical, social, and financial burden faced by minorities in the US leads to more harm from DCM in these groups. The overall goal of the project is to test whether ethnic minority patients carrying genes that cause DCM experience more adverse effects in part because of various medical, social, and financial burdens. The investigators will first establish the UIC Multi-ethnic DCM Biorepository to look for how often certain genes are found across different race-ethnicity and then ask the question if these genes impact the severity of DCM. Finally, the investigators will study how a person's environment can alter the course of their disease. Through this, the investigators hope and strive to ensure equal and adequate heart care for individuals regardless of their race-ethnicity.",[27,26],[64,27,270,271,272],"Genomics","Social Determinants of Health","Variant","2025-08-20",{"date":275,"type":35},"2025-08-28",{"date":277,"type":35},"2024-07-11",{"date":279,"type":20},"2038-12-31",{"name":281,"class":42},"University of Illinois at Chicago",{"id":283,"slug":4,"hasResults":10,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":43},"100587012","NCT06922851","Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)","Protein A Immunoadsorption in Dilated Cardiomyopathy: A Prospective, Multicenter, Randomized Study to Evaluate Efficacy and Safety (PRIA-DCM)","Inclusion Criteria:\n\n* Dilated cardiomyopathy\n* Presence of anti-β1-adrenergic receptor\n* Age 18-75 years\n* LVEF ≤ 40% determined by echocardiography (according to assessment of the local investigators)\n* NYHA class II-IV\n* Symptoms of heart failure ≥ 6 months\n* Treatment with guideline-directed medical therapy (GDMT) for ≥6 months and stable dose of ACEI\u002FARB\u002FARNI\u002Fβ-blocker\u002FSGLT2i\u002FMRA\u002FsGCa for ≥1 month (excluding diuretics)\n* Hemodynamically stable\n* Informed consent\n\nExclusion Criteria:\n\n* ICD implantation \\\u003C 1 month or CRT\u002FD implantation \\\u003C 6 months\n* Heart failure caused by other heart diseases\n* End-stage heart failure, inability to discontinue intravenously positive inotropic or vasoactive drugs\n* Expected survival \\\u003C 1 year\n* Hemoglobin \\\u003C 90g\u002FL\n* Any disease requiring immunosuppressive drugs\n* Commodities with other acute or severe illnesses, such as infections, severe hepatic or renal dysfunction, hematological diseases, malignant tumors, cachexia, autoimmune diseases, etc.\n* Previous treatment with immunoadsorption therapy or intravenous immunoglobulin therapy\n* Contraindications to extracorporeal circulation therapy, such as mental illness or consciousness disorders, shock, severe bleeding or bleeding tendency, coagulation dysfunction, multiple organ failure, etc.\n* Pregnancy\u002Flactation\n* Any other conditions that the researcher deems may increase the risk to the subject or interfere with the clinical trial and outcome assessment (such as excessive anxiety, alcohol or drug abuse, or cognitive impairment, etc.)",{"count":289,"type":20},60,[291],"NA","This study is a multicenter, dual-arm and randomized controlled clinical trial. Sixty patients with dilated cardiomyopathy and positive β1-adrenergic receptor autoantibodies were selected and randomly divided into an immunoadsorption group (receiving immunoadsorption therapy) and a control group in a 1:1 ratio. Changes in cardiac function, morphology and clinical outcomes were followed up and compared.",[26],"2025-05-30",{"date":296,"type":35},"2025-06-04",{"date":296,"type":20},{"date":299,"type":20},"2028-06-30",{"name":301,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":303,"slug":4,"hasResults":10,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":308,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":43},"100573108","NCT06741995","Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy","DCM Anti-Heart Antibody Diagnostic Kit Study--assessment of the Prognostic Impact of Anti-beta1AR Antibody and Anti-L-CaC Antibody in Patients With Dilated Cardiomyopathy","Inclusion Criteria:\n\n1. Age 18-75, any gender\n2. Diagnosed with dilated cardiomyopathy\n3. Subjects or their legal guardians are fully informed of the nature and risks of the study, participate voluntarily, and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Serious uncontrolled infection at enrolment (\"uncontrolled\" is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment)\n2. Uncontrolled active bleeding at enrollment\n3. Pregnancy or breastfeeding\n4. Combination of serious diseases affecting survival, such as tumors, with a life expectancy of less than one year\n5. Previous heart transplant or implantation of a cardiac assist device\n6. Patients with poor compliance who are unable to complete the full course of the study\n7. Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse\u002Faddiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.",{"count":309,"type":20},1000,"Background of the study The etiology of dilated cardiomyopathy (DCM) is complex and involves a variety of genetic, environmental, and immunologic factors. Autoimmune reactions (especially anti-cardiac autoantibodies) play an important role in the development of DCM. In recent years, several clinical studies have suggested that anti-β1AR and anti-L-CaC antibodies are associated with cardiovascular death, ventricular tachycardia, and sudden death in patients with DCM, which is of great value in the prognostic evaluation of DCM. However, most of these studies are single-center studies with small sample sizes and non-uniform testing methods. In this study, we will use a multicenter, prospective cohort study to follow up DCM patients in China for a period of 3 years, to further accurately assess the clinical predictive value of anti-β1AR antibody and anti-L-CaC antibody on the prognosis of DCM patients, and to provide epidemiological information as well as targeted therapeutic targets for DCM.\n\nAims of the study A multicenter, prospective cohort study of anti-β1AR and anti-L-CaC antibodies for prognostic assessment of DCM patients, enrolling 1,000 DCM patients, to further accurately assess the prognostic value of the anti-AHA assay for DCM patients, and to provide targets for targeted treatment of DCM.",[26],"2025-04-08",{"date":314,"type":35},"2025-04-11",{"date":316,"type":35},"2024-12-17",{"date":318,"type":20},"2027-12-17",{"name":301,"class":42},{"id":321,"slug":4,"hasResults":10,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":327,"targetDuration":4,"studyType":21,"phases":329,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":43},"100577162","NCT06794710","Early Identification and Treatment of Rare Cardiomyopathy Cohorts","Early Identification and Treatment of Rare Myocardium by Multimodal Imaging (EARLY-MYO-RARE)","EARLY-MYO-RARE","Inclusion Criteria:\n\n* Age 18-75 years old.\n* Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.\n* No history of structural heart disease, and the Framingham score \\<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography\u002Fcoronary CT\u002Fexercise platelet).\n* Creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula).\n* LVEF ≥50% assessed by Echocardiography.\n* QT interval \\< 470 ms.\n* Providing written informed consent.\n\nExclusion Criteria:\n\n* Presence of acute\u002Fchronic renal impairment (GFR \\<50\u002Fml\u002Fmin\u002F1.73m2).\n* History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure.\n* Presence of contraindications to CMR.",{"count":328,"type":20},300,[291],"This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.",[174,26,332,333],"Metabolic Cardiomyopathy","Restrictive Cardiomyopathy",[335],"rare cardiomyopathy, cardiac multimodal imaging, myocardial impairment","2025-01-21",{"date":338,"type":35},"2025-01-27",{"date":340,"type":20},"2025-02-01",{"date":342,"type":20},"2027-09-30",{"name":344,"class":42},"RenJi Hospital",{"id":346,"slug":4,"hasResults":10,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":196,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":353,"conditions":354,"keywords":358,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100573590","NCT06748261","AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","Artificial Intelligence-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary Computer Tomography Angiography","Atlantis","Cardiomyopathy cohort:\n\n* Inclusion Criteria:\n\n  1. A clinical diagnosis of cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, cardiac amyloidosis, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and coronary artery disease\u002Fischemic heart disease.\n  2. At least one CCTA before surgery or implantable device treatment.\n* Exclusion Criteria:\n\n  1. No recorded diagnosis of cardiomyopathy or undetermined type of cardiomyopathy.\n  2. A clinical diagnosis of secondary cardiac abnormalities due to other organic or systemic diseases.\n  3. Surgery or implantable device treatment before CCTA examination.\n\nControl cohort:\n\n* Inclusion Criteria: participants with at least one CCTA examination.\n* Exclusion Criteria: clinical diagnosis of cardiovascular diseases (including cardiomyopathy, history of myocardial infarction, history of cardiac surgery, stent implantation, ICD implantation and so on) or secondary cardiac abnormalities due to systemic diseases.",{"count":142,"type":20},"The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in patients with suspected coronary artery diseases. This study aims to develop a computerized CCTA interpretation using artificial intelligence for multi-label classification task to assist cardiomyopathy diagnosis in the clinical workflow.",[98,174,26,333,355,356,357,203,99],"Amyloid Cardiomyopathy","Ischemic Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy",[359,99,360,361],"Cardiac computer tomography angiography","Artificial intelligence","Diagnosis","2024-12-23",{"date":364,"type":35},"2024-12-27",{"date":366,"type":20},"2024-12-30",{"date":368,"type":20},"2025-12-30",{"name":370,"class":42},"Shanghai Zhongshan Hospital",{"id":372,"slug":4,"hasResults":10,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":377,"targetDuration":379,"studyType":119,"phases":4,"briefSummary":380,"conditions":381,"keywords":394,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":43},"100562769","NCT06607471","Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","AINICM","Inclusion Criteria:\n\n* Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.\n* Clinical suspicion of NICM, and\u002For proven diagnosis of any NICM and\u002For genotype consistent with any NICM.\n\nNICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic\u002Fautoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.\n\nExclusion Criteria:\n\n* Absent informed consent.\n* Proven diagnosis of cardiac disease alternative to NICM.\n* Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.\n* For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.",{"count":378,"type":20},15000,"30 Years","Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are \"overlap\" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the \"undefined\" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.\n\nTo the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and \"inflammatory\" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:\n\n1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.\n2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.\n\nBased on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.",[382,26,174,333,383,384,385,386,387,388,389,390,391,392,393],"Non-ischemic Cardiomyopathy","Arrhythmogenic Cardiomyopathy (AC, ARVD\u002FC)","Left Ventricular Noncompaction","Arrhythmogenic Mitral Valve Prolapse","Peripartum Cardiomyopathy","Anderson-Fabry Disease","Arrhythmic and Inflammatory Non-ischemic Cardiomyopathy","Inflammatory (Non-Arrhythmic) Non-ischemic Cardiomyopathy","Nonischemic Cardiomyopathy Sensu Strictu (Non-inflammatory, Non-arrhythmic)","Major Ventricular Arrhythmias, I.e. Sustained Ventricular Tachycardia, Ventricular Fibrillation, or Appropriate Therapy of Cardiac Device (defibrillators)","Overlapping Phenotype","Undefined Phenotypes",[395,396,397,398,399,400,401,402,403,404,405,406,407,408,179,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430],"Arrhythmogenic cardiomyopathy","Adverse event","Anderson-Fabry disease","Arrhythmic and Inflammatory Non-ischemic cardiomyopathy","Arrhythmogenic mitral valve prolapse","Anti tachycardia pacing","Bradiarrhythmias","Cardiac magnetic resonance","Cardiac resynchronization therapy with defibrillator","Computed tomography","Development Safety Update Report","Ethics Committee","Electroanatomical map","Electrocardiogram","Good Clinical Practice","Hypertrophic cardiomyopathy","Implantable cardioverter defibrillator","Informed Consent Form","International Conference on Harmonization","Immunomodulatory therapy","Late gadolinium enhancement","Left ventricular ejection fraction","Left ventricular noncompaction","Last Visit of Last Subject","Myocardial inflammation","Non-ischemic cardiomyopathies","Positron emission tomography","Pacemaker","Peripartum cardiomyopathy","Premature ventricular complexes","Serious Adverse Event","Supraventricular arrhythmias","Ventricular arrhythmias","Ventricular fibrillation","Ventricular tachycardia (sustained)","sudden cardiac death","2024-09-18",{"date":433,"type":35},"2024-09-23",{"date":435,"type":35},"2018-01-30",{"date":437,"type":20},"2035-12-31",{"name":439,"class":42},"Scientific Institute San Raffaele",""]